TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23956164

Group type: EXPERIMENTAL
Intervention: Iron supplementation (3 mg/kg/day of elemental iron and multivitamins)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Multivitamins alone (control group)
Number of subjects: 209
Study: 21788264

Group type: EXPERIMENTAL
Intervention: Soft insole with a semi-rigid rearfoot medial wedge
Number of subjects: 24

Group type: COMPARATOR
Intervention: Soft insole without corrective posting
Number of subjects: 24
Study: 19528561

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (elemental calcium, 1500 mg/d)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 17426409

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 83
Study: 15383014

Group type: EXPERIMENTAL
Intervention: 20 mg of elemental iron per day
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: 40 mg of elemental iron per day
Number of subjects: 526

Group type: COMPARATOR
Intervention: 0 mg of elemental iron (placebo)
Number of subjects: 526
Study: 11465525

Group type: EXPERIMENTAL
Intervention: Granisetron (1-1.5 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9682398

Group type: EXPERIMENTAL
Intervention: cell culture-derived vaccine
Number of subjects: 112

Group type: COMPARATOR
Intervention: egg-derived vaccine
Number of subjects: 112
Study: 7801297

Group type: EXPERIMENTAL
Intervention: Alcohol-exposed group (rats)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (rats)
Number of subjects: 0
Study: 3410479

Group type: EXPERIMENTAL
Intervention: Activated charcoal (20 g)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 77
Study: 29742959

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 142
Study: 28182700

Group type: EXPERIMENTAL
Intervention: Nyaditum resae® (NR)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 25328994

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 33
Study: 23642976

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 38
Study: 21463471

Group type: EXPERIMENTAL
Intervention: Single flow rate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Double flow rate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quadruple flow rate
Number of subjects: 20
Study: 17916665

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg with perindopril 4-8 mg added as needed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as needed
Number of subjects: 0
Study: 16433964

Group type: EXPERIMENTAL
Intervention: Milk containing 2.0 g CPP-ACP/l
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Milk containing 5.0 g CPP-ACP/l
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 10
Study: 14657887

Group type: EXPERIMENTAL
Intervention: Peanut skin prick tests (SPTs) and oral peanut challenges for groups 2 and 4 with positive SPT responses; peanut-specific IgE measurement for groups 2 and 4 with IgE levels < 15 kU/L.
Number of subjects: 7768
Study: 10699651

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Moxisylyte
Number of subjects: 49
Study: 9099448

Group type: EXPERIMENTAL
Intervention: Flunarizine 30 mg oral dose
Number of subjects: 64
Study: 8418692

Group type: EXPERIMENTAL
Intervention: Vertical Banded Gastroplasty (VBG)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Vertical Gastric Bypass (GB)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Isolated Gastric Bypass (IGB)
Number of subjects: 106
Study: 3096723

Group type: EXPERIMENTAL
Intervention: Methohexitone 1.5-2 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil 7 micrograms kg‐1
Number of subjects: 60
Study: 29316946

Group type: EXPERIMENTAL
Intervention: Combined cognitive behavioural group psychotherapy and physiotherapy (9 weekly sessions with a 4-week break between modules)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (Control group)
Number of subjects: 36
Study: 26867161

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 3213

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Negative screening result
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Positive screening result
Number of subjects: 3213
Study: 25489295

Group type: EXPERIMENTAL
Intervention: Peer coaching intervention
Number of subjects: 540
Study: 23265025

Group type: EXPERIMENTAL
Intervention: PBVO2max
Number of subjects: 24

Group type: COMPARATOR
Intervention: PBPA
Number of subjects: 24
Study: 20510642

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for overweight men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for overweight women
Number of subjects: 0
Study: 18716157

Group type: EXPERIMENTAL
Intervention: Resveratrol (at concentrations detected in plasma after wine intake)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no resveratrol, just wine intake)
Number of subjects: 20
Study: 15882362

Group type: EXPERIMENTAL
Intervention: Telephone intervention delivered by a specialist nurse
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study: 12666731

Group type: EXPERIMENTAL
Intervention: 1% lindane shampoo alone (group 1)
Number of subjects: 7495

Group type: EXPERIMENTAL
Intervention: 1% lindane shampoo and oral trimethoprim/sulfamethoxazole (group 2)
Number of subjects: 7495
Study: 10547175

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Antidepressants (sertraline hydrochloride)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combined exercise and medication
Number of subjects: 156
Study: 8683243

Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2)
Number of subjects: 242
Study: 1805048

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatine (IPM/CS) 1 g twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Latamoxef (LMOX) 2 g plus Tobramycin (TOB) 90 mg twice daily
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatine (IPM/CS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Latamoxef (LMOX) plus Tobramycin (TOB)
Number of subjects: 101
Study: 6402917

Group type: EXPERIMENTAL
Intervention: Oral tegafur (1 gm/m2/days 1‐21)
Number of subjects: 67

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-Fu, 500 mg/m2/days 1‐4, then 250 mg/m2 on days 6, 8, 10, 12)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patients switched to tegafur after failing on 5-Fu
Number of subjects: 67

Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral tegafur
Number of subjects: 67
Study: 31396686

Group type: EXPERIMENTAL
Intervention: Clinical assessment including swollen and tender joints count, patient and physician global assessment (PhGA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) assessment including synovitis or tenosynovitis by grey-scale (GS) and power Doppler (PD) of 42 structures
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Qualitative scoring method (0/1 based on algorithm)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: UltraSound Activity score (sum of swollen joint count, US qualitative score, and CRP)
Number of subjects: 281
Study: 29105958

Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (5 mg/80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (5 mg/160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (10 mg/160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebivolol/valsartan SPC (10 mg/320 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator weighted average (non-β-blocker/renin-angiotensin-aldosterone system inhibitor SPCs)
Number of subjects: 0
Study: 27399438

Group type: EXPERIMENTAL
Intervention: Total Disk Replacement (TDR)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 330
Study: 25384813

Group type: EXPERIMENTAL
Intervention: BRIGHT screening tool intervention
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3300
Study: 23007716

Group type: EXPERIMENTAL
Intervention: 3-minute slow-stroke back massage (SSBM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 40
Study: 20829325

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Counseling (motivational interviewing)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755

Group type: COMPARATOR
Intervention: Counseling (health education)
Number of subjects: 755
Study: 17272996

Group type: EXPERIMENTAL
Intervention: Low dose interferon-alpha (3 MU three times per week for 12 months)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High dose interferon-alpha (5 MU three times per week for 6 months)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall treatment (both doses)
Number of subjects: 23
Study: 16095546

Group type: EXPERIMENTAL
Intervention: Water-based exercise treatment
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 312
Study: 12463433

Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate ointment (GTN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 70
Study: 10513492

Group type: EXPERIMENTAL
Intervention: Training encounter with an arthritis educator along with standard experience in the arthritis clinic (n = 16)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard training in the arthritis clinic only (n = 11)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rheumatologists (n = 21) performing a comprehensive musculoskeletal examination
Number of subjects: 27
Study: 7677125

Group type: EXPERIMENTAL
Intervention: Cholesterol ester saturated fatty acid palmitic acid (16:0)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Phospholipid omega‐3 fatty acid docosapentaenoic acid (22:5)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (22:6)
Number of subjects: 188
Study: 2188928

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 i.v. every three weeks
Number of subjects: 24
Study: 483111

Group type: EXPERIMENTAL
Intervention: 20% mannitol-bisacodyl solution for oral use
Number of subjects: 0
Study: 31321771

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg once daily
Number of subjects: 3291

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 3291
Study: 28624340

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination of Teriparatide and Denosumab
Number of subjects: 94

Group type: COMPARATOR
Intervention: Denosumab to Teriparatide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Teriparatide to Denosumab
Number of subjects: 94

Group type: COMPARATOR
Intervention: Combination to Denosumab
Number of subjects: 94
Study: 24620015

Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonselective COX‐2 inhibitors
Number of subjects: 0
Study: 23508079

Group type: EXPERIMENTAL
Intervention: Non-TA-assisted PPV without ILM peeling (Group 1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Non-TA-assisted PPV with ILM peeling (Group 2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TA-assisted PPV without ILM peeling (Group 3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TA-assisted PPV with ILM peeling (Group 4)
Number of subjects: 96
Study: 21475006

Group type: EXPERIMENTAL
Intervention: StrataGraft skin substitute
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cadaveric allograft (standard of care)
Number of subjects: 15
Study: 19057981

Group type: EXPERIMENTAL
Intervention: Active LLLT (830 nm wavelength, 100 mW, spot size 0.0028 cm(2), 3‐4 J per point)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 20
Study: 16510331

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic salpingo‐oophorectomy (BPSO)
Number of subjects: 666
Study: 15120887

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 401

Group type: COMPARATOR
Intervention: CABG-CPB
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 401
Study: 12066422

Group type: EXPERIMENTAL
Intervention: Interpretation of target symbols (e.g., interpreting '>' as a right-pointing arrow or as a headlight shining to the left)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of target presentation during response planning or execution
Number of subjects: 0
Study: 9800669

Group type: EXPERIMENTAL
Intervention: hMG/hCG therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study: 7624530

Group type: EXPERIMENTAL
Intervention: Pulmonary artery temperature measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tympanic temperature measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral temperature measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 32
Study: 2515625

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg), 10 weeks after treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg), 6 weeks after treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Praziquantel (double dose of 40 mg/kg), within 10 days after treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 20
Study: 78718

Group type: EXPERIMENTAL
Intervention: Triprolidine (2.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (60 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30519751

Group type: EXPERIMENTAL
Intervention: First-trimester combined screening (FTCS)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Ultrasound plus cfDNA-based approach (US-cfDNA)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Overall screening for trisomies 18 and 13
Number of subjects: 688
Study: 28606735

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg twice daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg daily
Number of subjects: 75
Study: 25863535

Group type: EXPERIMENTAL
Intervention: Glucose optimization preoperatively
Number of subjects: 69

Group type: COMPARATOR
Intervention: No optimization preoperatively
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intensive glucose management postoperatively
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conservative glucose management postoperatively
Number of subjects: 69
Study: 23690197

Group type: EXPERIMENTAL
Intervention: Caloric diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: No diet (Control)
Number of subjects: 100
Study: 21557884

Group type: EXPERIMENTAL
Intervention: Active high-frequency rTMS (10 Hz at 110% of motor threshold, 1 session/day for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active high-frequency rTMS
Number of subjects: 30
Study: 19729401

Group type: EXPERIMENTAL
Intervention: Intervention group with treatment intensification
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Control group with treatment intensification
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Control group with BP levels above target
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Intervention group with BP levels above target
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Patients managed by practice nurse
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Both study groups with proper treatment intensification
Number of subjects: 1283
Study: 17250690

Group type: EXPERIMENTAL
Intervention: Anti-oxidant supplement (beta-carotene 9 mg/day, vitamin C 1500 mg/day, vitamin E 130 mg/day, zinc 45 mg/day, selenium 76 microg/day, garlic 150 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15180224

Group type: EXPERIMENTAL
Intervention: Arm-interval exercise program
Number of subjects: 14

Group type: COMPARATOR
Intervention: General rehabilitation program (Control)
Number of subjects: 14
Study: 11503466

Group type: EXPERIMENTAL
Intervention: Ligation of the SFJ with resorbable Vicryl
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ligation with Vicryl and continuous non‐resorbable stitching over (Prolene) the saphenous stump
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Non‐resorbable ligation of the SFJ (Ethibond)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ethibond ligation with Prolene stitching over the saphenous stump
Number of subjects: 400
Study: 9754182

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (CsA) 2% in maize oil
Number of subjects: 21
Study: 29317666

Group type: EXPERIMENTAL
Intervention: Rituximab 0.1 mg/m2
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rituximab 0.3 mg/m2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Proposed biosimilar 0.3 mg/m2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference product 0.3 mg/m2
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rituximab 1 mg/m2
Number of subjects: 32
Study: 28424854

Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy (NECT) as an add-on to treatment as usual
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: NECT
Number of subjects: 106
Study: 25532686

Group type: EXPERIMENTAL
Intervention: Tablet computer
Number of subjects: 223

Group type: COMPARATOR
Intervention: Paper
Number of subjects: 223
Study: 24217237

Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography (USG) mapping (Group B)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Classical methods (Group A)
Number of subjects: 314
Study: 19299763

Group type: EXPERIMENTAL
Intervention: Preoperative BNP elevation > or =50 pg/mL
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Combination of preoperative BNP elevation > or =50 pg/mL and postoperative cTn I elevation > or =2 ng/mL
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Normal preoperative BNP value
Number of subjects: 133
Study: 17560916

Group type: EXPERIMENTAL
Intervention: WISE-MD modules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional teaching methods
Number of subjects: 0
Study: 15470798

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reboxetine and Citalopram
Number of subjects: 36
Study: 11166379

Group type: EXPERIMENTAL
Intervention: Therapies aimed at inhibiting lymphoid cell apoptosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-cytokine and anti-inflammatory therapies
Number of subjects: 0
Study: 10335042

Group type: EXPERIMENTAL
Intervention: Rehabilitation (R)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 46
Study: 8573926

Group type: EXPERIMENTAL
Intervention: Moist toilet paper preparation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recycled toilet paper preparation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional toilet paper preparation
Number of subjects: 40
Study: 2561015

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg per os)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 861108

Group type: EXPERIMENTAL
Intervention: sodium nitroprusside
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: trimetaphan
Number of subjects: 45
Study: 30982604

Group type: EXPERIMENTAL
Intervention: Low total testosterone (TT <264 ng/dL)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Normal total testosterone (TT > 264 ng/dL)
Number of subjects: 781
Study: 26927283

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined model including INSIG1 expression level and splicing changes
Number of subjects: 150
Study: 25452062

Group type: EXPERIMENTAL
Intervention: Smoking cessation medication
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cessation group therapy
Number of subjects: 124
Study: 23591657

Group type: EXPERIMENTAL
Intervention: Opioid medications
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Nonopioid medications
Number of subjects: 1062
Study: 21692408

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg + Dexamethasone 4 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg + Dexamethasone 8 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 105
Study: 19491220

Group type: EXPERIMENTAL
Intervention: recombinant human GH (2 mg/d sc; n = 22)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (n = 8)
Number of subjects: 30
Study: 17326082

Group type: EXPERIMENTAL
Intervention: Double-dose (D(D)) Gd-DTPA
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single-dose (D(S)) Gd-DTPA
Number of subjects: 11
Study: 15075538

Group type: EXPERIMENTAL
Intervention: IL-2 immunotherapy with HAART
Number of subjects: 15

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 15
Study: 11465233

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 121
Study: 9571515

Group type: EXPERIMENTAL
Intervention: Smokers (n=467)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Nonsmokers (n=874)
Number of subjects: 1341